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Definitive diagnosis of heart failure with preserved ejection fraction (HFpEF) remains a challenge 
in the absence of invasive haemodynamic measurements.1,2 In part, this is because indirect 
measures of raised intracardiac increased filling pressures are imprecise and, in the case of 
natriuretic peptides may be influenced by comorbidities such as obesity (associated with lower 
concentrations) and chronic kidney disease and atrial fibrillation (associated with elevated 
concentrations). Moreover, left ventricular filling pressure may be normal at rest in patients with 
HFpEF, especially in individuals taking a diuretic, and only rise to abnormally high levels during 
exercise. 1,2 
Recently, two scores have been developed to help diagnose HFpEF. Reddy et al derived and 
validated a predictive model in two cohorts of patients referred for investigation of possible HFpEF, 
all of which underwent invasive haemodynamic exercise testing.3 Six variables were independent 
predictors of HFpEF: age >60 years, body mass index >30 kg/m2, hypertension treated with ≥2 
antihypertensive medications, atrial fibrillation, Doppler echocardiographic E/e’ >9, and pulmonary 
artery systolic pressure >35 mm Hg (Table). The resultant total H2FPEF score ranges from 0 to 9 
with the scores <2 and scores ≥6, respectively, reflecting a low or high likelihood of HFpEF. 
Individuals with an intermediate score (between 2 and 5) require further investigation e.g. invasive 
haemodynamic assessment. Of note, natriuretic peptides were not found to be predictive and are not 
included in this score. Unfortunately, as is often the case with scores of this type, an external 
validation raised doubts about its usefulness in less selected cohorts.4 
Recently, the Heart Failure Association of the ESC published a 4-step algorithm for the diagnosis 
HFpEF, based upon expert consensus.5 The suggested approach also uses a score, the HFA-PEFF 
score. Step 1 is assessment of the pre-test likelihood of HFpEF. Step 2 involves scoring based on 
major (2 point) and minor (1 point) criteria in three categories: function, morphology and 
biomarker. The resultant score includes some of the same variables as in the H2FPEF score, such as 
average E/e’ and tricuspid regurgitation-velocity, but is considerably more complex (Table). The 
pre-test probability step in the HFA-PEFF score includes consideration of some of the 
demographic/comorbidity variables in the H2FPEF score but does not allocate points for these. 
In the HFA-PEFF score, echocardiographic measurements are used to provide the supporting 
functional and morphological evidence and a natriuretic peptide (BNP or NT-proBNP) 
measurement the biomarker evidence in support of the diagnosis. Combined, the major and minor 
criteria yield a HFA-PEFF score of between 0 and 6 points (the maximum score allowed in each 
category is 2 points). An overall score of <2 points means HFpEF is unlikely. A score of 2-4 points 
indicates that a diagnosis of HFpEF is possible, but further work-up is needed, and a score of ≥5 
points that HFpEF is confirmed. The fourth and final step is an optional one where the goal is to 
define the specific aetiology. 
In this issue of the Journal, Barandiarán Aizpurua and colleagues have examined the performance 
of the second step in the HFA-PEFF algorithm in an important validation study in two single-centre 
patient cohorts.6 The Maastricht cohort included 270 patients referred with suspected HFpEF, the 
diagnosis of which was confirmed in 228. The Chicago cohort comprised only patients with 
confirmed diagnosis of HFpEF, all of which had been hospitalized previously. It is important to 
note that the final clinical diagnosis against which the score was compared included haemodynamic 
measurements during rest and exercise in only half of the Chicago cohort and none of the 
Maastricht cohort, yet this is arguably the gold standard against which any new test should be 
compared. As a result, the present study compared the HFA-PEFF score against a diagnosis of 
HFpEF made by experts using the same variables as those included in the score. Moreover, the ratio 
of HFpEF ‘cases’ to non-HFpEF ‘controls’ was very high. These two factors may have led to 
overestimation of the performance of the HFA-PEFF score. These caveats need to be taken into 
account when considering the apparently excellent results of the ‘rule-in approach’ with a 
specificity of 93%. Only 13 (3%) individuals from the Northwestern cohort and 3 (1%) from the 
Maastricht cohort had a diagnosis of HFpEF but a HFA-PEFF score of ≤1 point. Similarly, the 
performance of the score used as a ‘rule-out’ test, where a score of <2 had a sensitivity of 99% in 
the Maastricht cohort, may be overoptimistic, especially with the small number of non-HFpEF 
controls. 
Barandiarán Aizpurua and colleagues also suggest simplifications of the algorithm and, 
interestingly, found that natriuretic peptides had a similar performance to the total score. Although 
potentially very valuable, we cannot draw definitive conclusions about these observations in the 
present cohorts, because of the limitations discussed above. However, should natriuretic peptides 
be confirmed as useful as the HFA-PEFF score, clinical practice could be simplified greatly. 
The present report by Barandiarán Aizpurua and colleagues is a very welcome first step in 
evaluating the HFA-PEFF score and hopefully more investigators will evaluate this and the 
H2FPEF score in further cohorts of less selected patients, including a larger proportion of patients 
without a final diagnosis of HFpEF. An evaluation of both scores simultaneously in the same cohort 
will be particularly important given the simplicity of the H2FPEF score, should it perform as well 
as the HFA-PEFF score. Although difficult, it will be particularly important to test both scores 
against the gold standard of invasive measurements of filling pressures, including pressure during 
exercise. Which if any of these two scores will prove useful in the longer term remains to be seen 
and further iterations of this type of approach may emerge as a result of future investigation. 





Table: Comparison of the H2FPEF and HFA-PEFF scores 
 
 H2FPEF HFA-PEFF (Step 2)* 
Variables included (points)   
Demographics Age >60 years (1) 
Body mass index >30 kg/m2 (2) 
- 
Co-morbidity Hypertension treated with ≥2 
antihypertensive medications (1) 
Atrial fibrillation (3) 
- 
Cardiac morphology - LAVI >34 ml/m2 (2) or 
LVMI >149/122 gm2 (m/w) and RWT >0.42 
(2) 
 
LAVI 29-34 ml/m2 (1) or LVMI >115/95 gm2 
(m/w) (1) or RWT >0.42 (1) or LV wall 
thickness ≥12 mm Cardiac function/ 
non-invasive 
haemodynamics 
Average E/e’ х9 (1) 
TR velocity >2.8 m/s (PASP >35 mm Hg) 
(1) 
Average E/e’ ≥15 (2) or septal e’ <7cm/s 
(2) or 
lateral e’ <10cm/s (2) 
or TR velocity >2.8 m/s (PASP >35 mm Hg) 
(2) 
 
verage E/e’ 9-14 (1) or GLS <16% (1) 
Natriuretic peptides - NT-proBNP >220 pg/ml (2) or BNP >80 
pg/ml 
(2)  [AF: NT-proBNP >660 pg/ml (2) or BNP 
>240 pg/ml (2)] 
 
NT-proBNP 125-220 pg/ml (1) or BNP 35-80 
pg/ml (1)  [AF: NT-proBNP 365-660 pg/ml 
(1) 
or BNP 105-240 pg/ml (1)] 
Scores <2  low (HFpEF unlikely) 
2-5 intermediate (further investigation) 
≥6  high (confirmed) 
<2  low (HFpEF unlikely) 
2-4 intermediate (further investigation) 
≥5  high (confirmed) 
 
H2FPEF: Heavy [body mass index >30 kg/m2, 2 points], Hypertension [≥2 
antihypertensive agents, 1 point΁, atrial Fibrillation [3 points], Pulmonary 
hypertension [right ventricular systolic pressure >35 mm Hg, 1  
point], Elder [age >60 years, 1 point], Filling pressure [Doppler E/e’ х9, 1 point΁) 
*HFA-PEFF: Maximum of 2 points per category (morphology, function or natriuretic peptides) 
 
 
AF = atrial fibrillation RWT = relative wall thickness LAVI = left atrial volume 
index LVMI = left ventricular mass index BNP = B-type natriuretic peptide  NT-
proBNP = N-terminal prohormone of BNP TR = tricuspid regurgiation PASP = 
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